PXD038510

PXD038510 is an original dataset announced via ProteomeXchange.

Title	Multi-omics study for drug resistance investigation
Description	Palbociclib is a specific CDK4/6 inhibitor that has been widely applied in multiple tumor types. Different from cytotoxic drugs, the anticancer mechanism of palbociclib mainly depends on cell cycle inhibition. Therefore, the resistance mechanism is different. For clinical cancer patients, drug resistance is inevitable for almost all cancer therapies including palbociclib. We have trained palbociclib resistance cell lines in vitro to monitor the clinical situation and applied LC-MS-based proteomic and glycoproteomic technology to deeply understand the underly mechanism behind the resistance. As a result, the resistant cells mainly relied on an alternative metabolic pathway to keep proliferation based on proteomic analysis. Metabolic processes related to carbohydrates, lipids, DNA, cellular proteins, glucose, and amino acids were observed to be upregulated. Most dramatically, the protein expression of COX-1 and NDUFB8 have been detected to be significantly overexpressed. When a COX-1 inhibitor was hired to combine with palbociclib, a synergistic effect could be obtained, suggesting the altered COX-1 involved metabolic pathway is the major reason for the acquired palbociclib resistance. Additionally, through glycoproteomic analysis, the global glycosylation was found to be elevated in the palbociclib-resistant cells. Moreover, the integration of glycoproteomic data allowed us to detect a lot more proteins that have been glycosylated with low abundance, these proteins were normally overwhelmed by those highly abundant proteins during regular proteomic LC-MS detection. These low abundant glycoproteins are mainly involved in the cellular biology process of cell migration, regulation of chemotaxis, as well as glycoprotein metabolic process which offered us a great more detail on the roles the alternated glycan modification played during drug resistance. The high efficiency of the integrated proteomic and N-glycoproteomic workflow in discovering drug resistance mechanisms paves the new way for drug development. With a clear understanding of the resistance mechanism, new drug targets and drug combinations could be designed to resensitize the resistant tumors.
HostingRepository	iProX
AnnounceDate	2022-11-30
AnnouncementXML	Submission_2023-01-09_23:34:12.826.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Zhichao Xue
SpeciesList	scientific name: Homo sapiens; NCBI TaxID: 9606;
ModificationList	No PTMs are included in the dataset
Instrument	Orbitrap Fusion; LTQ Orbitrap Elite

Revision	Datetime	Status	ChangeLog Entry
0	2022-12-01 20:08:40	ID requested
⏵ 1	2023-01-09 23:34:13	announced

Dataset with its publication pending

submitter keyword: LC-MS1, Proteomics, Metabolomics, Glyproteomics, Drug resistance, Cancer biologyc

Xiaoyun Gong
contact affiliation	National institute of metrology, China
contact email	gxy@nim.ac.cn
lab head
Zhichao Xue
contact affiliation	National institute of metrology, China
contact email	360957988@qq.com
dataset submitter

iProX dataset URI